Diamyd Medical

📍 Stockholm, Sweden👥 39 employees💰 Last funded May 2021
Pharmaceutical Manufacturing🌐 diamyd.com
Website LinkedIn
Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes. The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umeå for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB. The Diamyd Medical share is traded on Nasdaq First North Growth Market, ticker DMYD B.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Diamyd Medical?
Diamyd Medical has 1 investors on record on gritt.io.
When did Diamyd Medical last raise funding?
The most recent investment in Diamyd Medical recorded on gritt.io was in May 2021.
What industry is Diamyd Medical in?
Diamyd Medical operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Diamyd Medical based?
Diamyd Medical is headquartered in Stockholm, Sweden.